A comprehensive analysis of methods for assessing polygenic burden on Alzheimer’s disease pathology and risk beyond APOE

Abstract Genome-wide association studies have identified dozens of loci that alter the risk to develop Alzheimer’s disease. However, with the exception of the APOE-ε4 allele, most variants bear only little individual effect and have, therefore, limited diagnostic and prognostic value. Polygenic risk scores aim to collate the disease risk distributed across the genome in a single score. Recent works have demonstrated that polygenic risk scores designed for Alzheimer’s disease are predictive of clinical diagnosis, pathology confirmed diagnosis and changes in imaging biomarkers. Methodological innovations in polygenic risk modelling include the polygenic hazard score, which derives effect estimates for individual single nucleotide polymorphisms from survival analysis, and methods that account for linkage disequilibrium between genomic loci. In this work, using data from the Alzheimer’s disease neuroimaging initiative, we compared different approaches to quantify polygenic disease burden for Alzheimer’s disease and their association (beyond the APOE locus) with a broad range of Alzheimer’s disease-related traits: cross-sectional CSF biomarker levels, cross-sectional cortical amyloid burden, clinical diagnosis, clinical progression, longitudinal loss of grey matter and longitudinal decline in cognitive function. We found that polygenic scores were associated beyond APOE with clinical diagnosis, CSF-tau levels and, to a minor degree, with progressive atrophy. However, for many other tested traits such as clinical disease progression, CSF amyloid, cognitive decline and cortical amyloid load, the additional effects of polygenic burden beyond APOE were of minor nature. Overall, polygenic risk scores and the polygenic hazard score performed equally and given the ease with which polygenic risk scores can be derived; they constitute the more practical choice in comparison with polygenic hazard scores. Furthermore, our results demonstrate that incomplete adjustment for the APOE locus, i.e. only adjusting for APOE-ε4 carrier status, can lead to overestimated effects of polygenic scores due to APOE-ε4 homozygous participants. Lastly, on many of the tested traits, the major driving factor remained the APOE locus, with the exception of quantitative CSF-tau and p-tau measures.

[1]  J. Hardy,et al.  Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition , 2019, Annals of neurology.

[2]  Alicia R. Martin,et al.  Geographic Variation and Bias in the Polygenic Scores of Complex Diseases and Traits in Finland. , 2019, American journal of human genetics.

[3]  Sterling C. Johnson,et al.  The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory , 2019, Nature Communications.

[4]  Michael D. Greicius,et al.  A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward , 2019, Neuron.

[5]  Eden R Martin,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[6]  Nick C Fox,et al.  Polygenic risk and hazard scores for Alzheimer's disease prediction , 2019, Annals of clinical and translational neurology.

[7]  Dominic Holland,et al.  Polygenic hazard score, amyloid deposition and Alzheimer’s neurodegeneration , 2019, Brain : a journal of neurology.

[8]  Timothy J. Hohman,et al.  Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk , 2019, Nature Genetics.

[9]  A. Saykin,et al.  Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging , 2018, Molecular Psychiatry.

[10]  Yang Ni,et al.  Polygenic prediction via Bayesian regression and continuous shrinkage priors , 2018, Nature Communications.

[11]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[12]  Sebastien Ourselin,et al.  Genetic study of multimodal imaging Alzheimer’s disease progression score implicates novel loci , 2018, Brain : a journal of neurology.

[13]  R. Desikan,et al.  Interpreting Alzheimer disease polygenic scores , 2018, Annals of neurology.

[14]  A. Fagan,et al.  Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms , 2018, Alzheimer's & Dementia.

[15]  Erdogan Taskesen,et al.  Functional mapping and annotation of genetic associations with FUMA , 2017, Nature Communications.

[16]  A. Myers,et al.  Polygenic risk score analysis of pathologically confirmed Alzheimer disease , 2017, Annals of neurology.

[17]  O. Andreassen,et al.  Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition , 2017, bioRxiv.

[18]  Lilah M. Besser,et al.  Polygenic hazard scores in preclinical Alzheimer’s disease , 2017, bioRxiv.

[19]  D. Schaid,et al.  Polygenic risk scores in familial Alzheimer disease , 2017, Neurology.

[20]  Lilah M. Besser,et al.  Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score , 2017, PLoS medicine.

[21]  R. Buckner,et al.  Polygenic risk of Alzheimer disease is associated with early- and late-life processes , 2016, Neurology.

[22]  M. Gill,et al.  Common polygenic variation enhances risk prediction for Alzheimer's disease. , 2015, Brain : a journal of neurology.

[23]  P. Visscher,et al.  Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores , 2015, bioRxiv.

[24]  Jack Euesden,et al.  PRSice: Polygenic Risk Score software , 2014, Bioinform..

[25]  Andre Altmann,et al.  Sex modifies the APOE‐related risk of developing Alzheimer disease , 2014, Annals of neurology.

[26]  Richard Durbin,et al.  Efficient haplotype matching and storage using the positional Burrows–Wheeler transform (PBWT) , 2014, Bioinform..

[27]  M. Greicius,et al.  Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction , 2013, Brain Imaging and Behavior.

[28]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[29]  A. Dale,et al.  Higher Rates of Decline for Women and Apolipoprotein E ε4 Carriers , 2013, American Journal of Neuroradiology.

[30]  Chia-Yen Chen,et al.  Improved ancestry inference using weights from external reference panels , 2013, Bioinform..

[31]  F. Dudbridge Power and Predictive Accuracy of Polygenic Risk Scores , 2013, PLoS genetics.

[32]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[33]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[34]  R. Buckner,et al.  The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. , 2012, Cerebral cortex.

[35]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[36]  David B. Witonsky,et al.  Reconstructing Native American Population History , 2012, Nature.

[37]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[38]  O. Delaneau,et al.  A linear complexity phasing method for thousands of genomes , 2011, Nature Methods.

[39]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[40]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[41]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[42]  Michael Weiner,et al.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection , 2010, NeuroImage.

[43]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[44]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[45]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[46]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[47]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.